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The phase-variable locus lex2 is required for expression of a Haemophilus influenzae lipopolysaccharide (LPS)
epitope of previously unknown structure. This epitope, which is reactive with monoclonal antibody (MAb) 5G8,
has been associated with virulence of type b strains. When strain RM118 (from the same source as strain Rd),
in which the lex2 locus and MAb 5G8 reactivity are absent, was transformed with lex2 DNA, transformants that
were reactive with MAb 5G8 were obtained. Surprisingly, the 5G8 reactivity of these transformants was phase
variable, although the lex2 locus lacked tetrameric repeats and was constitutively expressed. This phase
variation was shown to be the result of phase-variable expression of phosphorylcholine (PCho) such that MAb
5G8 reacted only in the absence of PCho. Structural analysis showed that, compared to RM118, the lex2 trans-
formant had acquired a tetrasaccharide, Gal-1,4-Gal-1,4-Glc-1,4-Glc-1,4, linked to the proximal heptose
(HepI). A terminal GalNAc was detected in a minority of glycoforms. LPS derived from a mutant of RM7004,
a virulent type b strain which naturally expresses lex2 and has LPS containing the same tetrasaccharide linked
to HepI as the sole oligosaccharide extension from the inner core, confirmed that GalNAc is not a part of the
MAb 5G8-reactive epitope. Thus, MAb 5G8 specifically binds to the structure Gal-1,4-Gal-1,4-Glc-1,4-
Glc- attached via a 1,4 linkage to HepI of H. influenzae LPS, and we show that the ability to synthesize this
novel tetrasaccharide was associated with enhanced bacterial resistance to complement-mediated killing.
Haemophilus influenzae is a human-specific, gram-negative
coccobacillus. It is usually a commensal present in the upper
respiratory tract but has the propensity to cause disease. En-
capsulated strains, mainly H. influenzae type b (Hib) strains,
cause meningitis and septicemia in unvaccinated children (30),
and nonencapsulated strains typically cause acute lower respi-
ratory tract infections and otitis media.
A major component of the H. influenzae cell wall influencing
both commensal and virulence behavior is the lipopolysaccha-
ride (LPS) molecule (5, 14, 17). The structure of H. influenzae
LPS includes a conserved triheptose (HepI to HepIII) inner
core linked via a single 2-keto-3-deoxy-octulosonic acid (Kdo)
molecule to lipid A, from which there are oligosaccharide
extensions (outer core), mainly hexose sugars, that vary from
one strain to another (see Fig. 1). H. influenzae LPS lacks the
repetitive side chains (often referred to as O antigens) typical
of some pathogenic gram-negative bacteria but displays great
complexity in its outer core sugars and other, nonsugar sub-
stituents such as phosphorylcholine (PCho) (20). Several of
these sugars and nonsugar substituents of H. influenzae LPS
are phase variable, a finding initially demonstrated by colony
immunoblotting using monoclonal antibodies (MAbs) specific
for H. influenzae LPS (16, 17). Of these MAbs, most Hib
disease isolates were reactive with MAb 4C4 and some also
reacted with MAb 5G8 (7). Spontaneous acquisition of reac-
tivity to MAb 5G8 by a relatively avirulent, serum-sensitive Hib
strain was associated with resistance to killing by infant rat
serum and enhanced virulence in an infant rat model of infec-
tion (16). Similar observations were reported for other Hib
strains (17) and for strains already expressing the MAb 4C4-
reactive epitope (2, 3, 16, 17). Subsequent studies have showed
that MAb 4C4 binds to an epitope incorporating a terminal
digalactoside (Gal-1,4-Gal--) extending from the second
heptose (HepII) of the LPS of strain RM153 (32). Phase vari-
ation of this digalactoside is mediated by translational switch-
ing of two galactosyl transferase-encoding genes, lic2A (9) and
lgtC (12), that contain tetranucleotide repeats within the 5
ends of their reading frames. While the structure of the MAb
5G8-reactive epitope is unknown, its expression is associated
with the expression of the MAb 4C4-reactive epitope and with
the expression of the phase-variable locus lex2 (15). This locus
comprises two reading frames: lex2A, which contains tet-
ranucleotide repeats, and lex2B. Both genes are necessary for
the addition of a second glucose to the glucose attached to
HepI of H. influenzae LPS (6).
We have now fully characterized the MAb 5G8-reactive
epitope in two strains for which the detailed structure of the
LPS is available, RM7004 and RM118 (Fig. 1) (21, 23). We
used genetics to modify RM118, a strain which does not nat-
urally react with MAb 5G8, so that it expresses lex2, synthesizes
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tetrasaccharide Gal-1,4-Gal-1,4-Glc-1,4-Glc-1,4, and dis-
plays phase-variable MAb 5G8 reactivity as well as enhanced
bacterial resistance to complement-mediated killing.
MATERIALS AND METHODS
Bacterial strains and culture conditions. The H. influenzae type d-derived
strain RM118 is from the same source as strain Rd used for the genome se-
quencing project (4), and the type b strain RM7004 is a disease isolate (31).
H. influenzae strains were grown at 37°C in brain heart infusion medium supple-
mented with hemin (10 g ml1) and NAD (2 g ml1) in liquid medium or
Levinthals supplement (10% [vol/vol]) (1) on solid medium. When appropriate,
kanamycin (10 g ml1) or tetracycline (4 g ml1) was included in the medium.
Escherichia coli strain DH5 was used to propagate cloned plasmids and was
grown at 37°C in Luria-Bertani broth (26) supplemented with ampicillin (100 g
ml1), kanamycin (30 g ml1), and tetracycline (12 g ml1) as appropriate.
Recombinant DNA methodology and nucleotide sequence analysis. Restric-
tion endonucleases and DNA-modifying enzymes were obtained from Boehr-
inger Mannheim and used according to the manufacturer’s instructions.
Plasmid DNA was prepared from E. coli strains by the alkaline-lysis method
(26). Chromosomal DNA was prepared from Haemophilus by the method de-
scribed previously (22). Oligonucleotide primers were purchased from Sigma-
Genosys (Cambridge, United Kingdom). PCR amplification was performed us-
ing Taq polymerase (Promega) in 50-l reaction volumes in a Perkin-Elmer
DNA thermal cycler. The Qiaex II gel extraction kit (Invitrogen) was used to
purify restriction-digested DNA fragments prior to their ligation to generate
plasmid constructs.
Preparation of plasmid constructs containing modified LPS genes. The plas-
mid construct p112 incorporating the lpsA gene disrupted by a Kanr gene was
previously described (10). Plasmid clone p113 was generated by restricting p112
with EcoRI to remove the Kanr gene and replace it with the Tetr gene (derived
from Tn10).
To delete genes HI0753 and HI0754 from H. influenzae strain RM118, primers
LEX2PR1 (5-TATCCCAAGCTTGATTCAGTTTGGTTTGCAGGA-3) and
lex2CHP1 (5-GGAATGGGCAACTTATGGCG-3) were used to amplify by
PCR a 2,759-bp fragment encompassing these genes from strain RM118 chro-
mosomal DNA. The product obtained was cloned into plasmid pCR2.1, gener-
ating clone pCR2.1HI0753-4. The Kanr gene in the plasmid replicon was inac-
tivated by restricting with NcoI, which cuts the plasmid uniquely in this gene,
treating with Klenow enzyme and deoxynucleotide triphosphates to fill in the
recessed ends, and religating the plasmid. The resultant plasmid, pCR2.1HI0753-
4N, was digested with SspI to remove a region spanning from 79 bp downstream
of the potential initiation codon of HI0753 to 330 bp upstream of the poten-
tial stop codon of HI0754. The HincII fragment of pUC4k (Pharmacia)
incorporating the Kanr gene was ligated in place of this region to give plasmid
pCR2.1HI0753-4Nk.
A PCR-based method was used to generate an in-frame deletion of the repeat
tract of lex2A in plasmid pB7004Elex2 (6). Primers BgA (5-GCAAGATCTTC
AAGACTATCTAAAATTTC-3) and BgB (5-GGAAGATCTGAGTGACTT
AAATAGTACA-3) were designed to anneal immediately adjacent to, but on
opposite sides of, the repeat tract of lex2A and in reverse orientations, and each
has a unique BglII restriction enzyme site near its 5 end. These primers were
each used pairwise with an appropriate plasmid-specific primer to generate
products from pB7004Elex2. A PCR amplification product incorporating the 5
end of lex2A and the 3 end of the upstream gene purL was obtained by PCR
amplification with primer BgA and the plasmid-specific T7 universal primer (28).
This product was ligated into pCR2.1 (Invitrogen) to generate clone
pCR2.1BgA. A PCR amplification product incorporating a sequence 3 of the
repeats of lex2A and lex2B and the 3 end of gene HI0755 was obtained using
primer BgB and the plasmid-specific M13 reverse universal primer (28) and was
ligated into pCR2.1 to generate clone pCR2.1BgB. The cloned fragments re-
leased by digestion of pCR2.1BgA with SnaBI-BglII and pCR2.1BgB with BglII-
StyI were ligated into SnaBI-StyI-digested pB7004Elex2 (6), replacing the orig-
inal lex2 and adjacent sequence. Correct clones were designated pBlex25-
GCAA-3.
For selection following transformation, an antibiotic resistance gene was in-
serted into the construct downstream of lex2B by using a restriction enzyme site
created by PCR. Primers BaA (5-CGCGGATCCACTGCTTTGTCTACTATA
TC-3) and BaB (5-CGCGGATCCTGTTAATGTTTATTTTTAAATATTAG-
3), each incorporating a BamHI site near its 5 end, were designed to anneal on
opposite strands and in reverse orientations from the nucleotide 27 bp down-
stream of the stop codon of lex2B. A PCR product incorporating most of lex2B
and the first 27 bp of the downstream intergenic sequence was generated using
primers BaA and P1 (5-GCGGTTGAATGCAAAGGG-3) and was ligated into
pCR2.1 to generate clone pCR2.1BaA. The region containing the remaining
intergenic sequence downstream of lex2B and most of the downstream gene,
HI0755, was amplified by PCR using primers BaB and P2 (5-ATGCCACGTG
AAATTTCCG-3) and chromosomal DNA of strain RM7004 as a template. The
product obtained was ligated into pCR2.1 to generate clone pCR2.1BaB. The
StyI-BamHI fragment of clone pCR2.1BaA, the Kanr gene of pUC4k (Pharma-
cia) released by digestion with BamHI, and the BamHI-XhoI fragment of clone
pCR2.1BaB were ligated into the plasmid pBlex25-GCAA-3 digested with
StyI and XhoI. The XhoI site is located in the polylinker of pBlex25-GCAA-3
downstream of lex2B. The clone was designated pBlex25-GCAA-3k. This con-
struct was sequenced using primer lex2seq (6) to verify the sequence of the DNA
where the repeats were deleted. Plasmid pBlex25-GCAA-3t was obtained
from pBlex25-GCAA-3k by replacement of the Kanr gene with the Tetr gene.
Transformation of H. influenzae. H. influenzae strains were transformed with
the appropriate linearized plasmid (8), and the recombinant strains were verified
by PCR amplification and Southern analysis (26).
Plasmid constructs pBlex25-GCAA-3k, pBlex25-GCAA-3t, and
pCR2.1HI0753-4N were used to transform strain RM118 to give strains
RM118lex2k, RM118lex2t, and RM118HI0753-4kan, respectively. Plas-
mid p112 was used to transform strain RM118lex2t to generate strain
RM118lex2tlpsA-k. Plasmid p113 was used to transform a mutant strain of
RM7004 disrupted in lic2C (RM7004lic2C-k) to generate strain RM7004lic2C-
klpsA-t.
Analysis of LPS by colony immunoblotting. A freshly grown single colony of
H. influenzae was serially diluted in phosphate-buffered saline, and an appropri-
ate dilution was plated to obtain approximately 500 CFU per plate. After over-
night growth, the colonies were transferred onto a nitrocellulose filter, dried, and
then subjected to reactions with the appropriate MAbs as previously described
(25).
FIG. 1. Schematic representation of the structure of the fully ex-
tended LPS glycoforms of H. influenzae strains RM7004 (A) and
RM118 (B). (A) A globotriose (Gal-1,4-Gal-1,4-Glc-1,4-) is linked
to the glucose attached to both HepI and HepII of the LPS of strain
RM7004, and a single galactose, partially replaced with PCho, is linked
to HepIII (21). (B) A single glucose, replaced with PCho, is linked to
HepI, and a globotetraose unit extends from HepIII of the LPS of
strain RM118 (23). Represented in the LPS structures are the follow-
ing molecules: heptose (Hep), glucose (Glc), galactose (Gal), phos-
phate (P), PCho, and phosphoethanolamine (PEtn). Dashed lines in-
dicate the substituents that are variably present. The sites of action of
key loci in LPS synthesis are indicated by arrows.
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Gel fractionation of LPS and Western immunoblotting. Whole-cell lysates of
H. influenzae strains were prepared as previously described (27) and then frac-
tionated by tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(PAGE) (18). LPS was visualized by staining with silver (Quicksilver; Amer-
sham) (24) or was electrophoretically transferred onto a nitrocellulose mem-
brane for Western analysis (29, 34).
LPS structural analyses. Structural analyses of LPS using mass spectrometry
(MS) and nuclear magnetic resonance (NMR) techniques were carried out as
described previously (19).
Serum resistance assay. Bacteria were assayed for survival against the killing
effect of normal human serum as described previously (11).
RESULTS
Engineering an RM118 strain expressing lex2 with acquired
reactivity to MAb 5G8. Plasmid pBlex25-GCAA-3k, incor-
porating lex2A and lex2B, was constructed with the tetranucle-
otide repeat tract of lex2A removed to leave a non-phase-
variable, constitutively translated gene. Any confounding effect
of lex2 phase variation upon analysis of function after transfer
into strain RM118 was therefore negated.
A minority of colonies of the recombinant strain RM118lex2k
reacted with 5G8, unlike the parent strain, which does not
react with this MAb (33). The remaining colonies showed no
reactivity (Fig. 2A). Several colonies showed a sectored phe-
notype, indicative of phase-variable expression of the respec-
tive LPS epitope. We tested the reactivity of this strain with
MAb 4C4, since 5G8 reactivity is associated with 4C4 reactivity
(7) and the latter is associated with the expression of a digal-
actoside in H. influenzae LPS (32). Unlike those of the parent
strain (Fig. 2C), most colonies of RM118lex2k reacted (
phenotype), while a minority of colonies demonstrated either
strong ( phenotype) or no ( phenotype) reactivity (Fig.
2B). When colonies of the  phenotype were isolated and the
cells were dispersed and replated, a minority of the resultant
colonies again displayed the  and  phenotypes (data not
shown). Thus, transformation of strain RM118 with the lex2
locus resulted in the phase-variable expression of an LPS epi-
tope, which is presumed to include a digalactoside.
In the genome sequence of strain Rd (equivalent to RM118),
in place of the lex2 locus are two genes, HI0753 and HI0754, of
unknown function (6). Reciprocal recombination in strain
RM118lex2k had replaced these two genes by the in-frame
FIG. 2. Analysis of LPS molecules of H. influenzae strains RM118lex2k and RM118 by colony immunoblotting with the indicated MAbs (A
to C) and by gel fractionation (D). The levels of MAb binding by individual colonies are shown by arrows and indicated by  or , representing
reactivity and no reactivity, respectively. The faint upper bands seen in the profile of RM118 LPS correspond to four sugar units that can be added
in the absence of lex2 (13).
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lex2 locus. To ensure that the altered LPS phenotype of this
strain was due to the gain of lex2 rather than the loss of genes
HI0753 and HI0754, these two genes were mutated in strain
RM118 by transformation with construct pCR2.1HI0753-4Nk.
Strain RM118HI0753-4k showed no alteration in the PAGE
fractionation pattern of LPS or in reactivity with MAbs 4C4
and 5G8 compared with the parent strain (data not shown).
Thus, disruption of HI0753 and HI0754 had no effect upon
LPS biosynthesis.
Characterization of the LPS of the lex2 transformant strain
RM118lex2k. PAGE fractionation of the LPS isolated from
strain RM118lex2k showed two or three additional lower-
mobility bands compared with the profile of the parent strain
(Fig. 2D). Thus, expression of lex2 in RM118 resulted in the
addition of sugars to the LPS of this strain.
MS analysis of purified O-deacylated LPS of strain RM118
lex2k indicated that three additional hexose and two addi-
tional HexNAc sugars were present in this strain compared to
the parent strain (Table 1). The presence of the first HexNAc
was detected subsequent to the incorporation of five hexoses,
and the presence of the second HexNAc was observed after the
incorporation of seven hexoses into the LPS of this strain. For
the latter glycoform, sugar composition analysis suggested a
glucose-to-galactose ratio of almost 1 to 1. This analysis also
indicated that both HexNAc residues were N-acetylgalactos-
amine (GalNAc) (Table 1). These data are consistent with our
prediction that the expression of lex2 in strain RM118 would
result in the addition of a further single glucose and a digal-
actoside to the glucose (GlcI) attached to HepI of the LPS of
this strain, as reported for strain RM7004 (6). In strain RM118,
GalNAc is the final residue added to the globotetraose unit at
the third heptose after assembly of four hexoses. Detection of
the addition of GalNAc in glycoforms comprising five or more
hexose sugars in strain RM118lex2k indicates that the addi-
tion of the glucose by lex2 to GlcI occurs prior to the addition
of the GalNAc of the globotetraose unit from HepIII.
Localization of the MAb 5G8 epitope in strain RM118lex2
tlpsA-k allows expression of only the oligosaccharide extension
from HepI. In the LPS of strain RM118, there is no oligosac-
charide extension from HepII (Fig. 1) (23). To confirm that the
additional sugars in the LPS of strain RM118lex2k were
added to the oligosaccharide extending from HepI, and not to
that extending from HepIII, lpsA, which is required for the
addition of the first glucose to HepIII of strain RM118 (Fig. 1),
was disrupted. Mutation of lpsA to give strain RM118lex2
tlpsA-k prevents any oligosaccharide extension from HepIII in
this strain background (11).
Upon colony immunoblotting of strain RM118lex2tlpsA-k
with MAb 5G8, a minority of colonies reacted ( phenotype)
while the remainder showed no reactivity with this MAb (data
not shown). This pattern of reactivity was similar to that of
RM118lex2k and confirms that the gain of reactivity with
MAb 5G8 is associated with the assembly of an oligosaccharide
chain extending from HepI. Upon colony immunoblotting of
strain RM118lex2tlpsA-k with MAb 4C4, a majority of colo-
nies demonstrated reactivity ( phenotype) while a minority
TABLE 1. Negative ion electrospray-MS data and proposed compositions of O-deacylated LPS molecules
from strains of RM118 transformed with lex2a
Strain
Result for:
Proposed composition of LPS





RM118lex2k 866.4 1,300.4 2,602.9 2,603.2 0.2 PCho, 3Hex, 3Hep, PEtn, Kdo-P, lipid A
907.4 1,362.6 2,725.9 2,726.3 0.2 PCho, 3Hex, 3Hep, 2PEtn, Kdo-P, lipid A
920.7 1,386.1 2,765.9 2,766.3 0.4 PCho, 4Hex, 3Hep, PEtn, Kdo-P, lipid A
961.8 1,443.4 2,888.8 2,889.3 0.5 PCho, 4Hex, 3Hep, 2PEtn, Kdo-P, lipid A
974.8 1,462.5 2,927.1 2,928.4 0.5 PCho, 5Hex, 3Hep, PEtn, Kdo-P, lipid A
1,015.9 1,524.5 3,050.8 3,051.4 0.8 PCho, 5Hex, 3Hep, 2PEtn, Kdo-P, lipid A
1,028.8 3,089.8 3,093.5 0.3 PCho, 6Hex, 3Hep, PEtn, Kdo-P, lipid A
1,042.7 3,131.5 3,131.6 0.4 PCho, 5Hex, HexNAc, 3Hep, PEtn, Kdo-P, lipid A
1,069.8 1,605.7 3,213.4 3,213.6 0.4 PCho, 6Hex, 3Hep, 2PEtn, Kdo-P, lipid A
1,083.6 1,625.9 3,253.9 3,254.7 1.0 PCho, 5Hex, HexNAc, 3Hep, 2PEtn, Kdo-P, lipid A
1,096.7 3,293.5 3,293.7 0.3 PCho, 6Hex, HexNAc, 3Hep, PEtn, Kdo-P, lipid A
1,137.5 1,707.0 3,415.6 3,416.7 0.5 PCho, 6Hex, HexNAc, 3Hep, 2PEtn, Kdo-P, lipid A
1,150.7 3,455.9 3,455.9 0.3 PCho, 7Hex, HexNAc, 3Hep, PEtn, Kdo-P, lipid A
1,191.8 3,577.8 3,578.9 0.3 PCho, 7Hex, HexNAc, 3Hep, 2PEtn, Kdo-P, lipid A
1,218.8 1,827.6 3,659.4 3,659.1 0.3 PCho, 7Hex, 2HexNAc, 3Hep, PEtn, Kdo-P, lipid A
RM118lex2tlpsA-k 1,056.2 2,114.4 2,113.9 0.1 1Hex, 3Hep, PEtn, Kdo-P, lipid A
1,056.2 2,114.4 2,113.9 0.1 1Hex, 3Hep, PEtn, Kdo-P, lipid A
1,118.0 2,237.4 2,236.9 0.1 1Hex, 3Hep, 2PEtn, Kdo-P, lipid A
1,139.0 2,279.4 2,279.9 0.2 PCho, 1Hex, 3Hep, PEtn, Kdo-P, lipid A
1,219.8 2,441.5 2,442.1 0.2 PCho, 2Hex, 3Hep, PEtn, Kdo-P, lipid A
1,281.5 2,565.0 2,565.1 0.2 PCho, 2Hex, 3Hep, 2PEtn, Kdo-P, lipid A
866.9 1,300.9 2,603.9 2,603.2 0.6 PCho, 3Hex, 3Hep, PEtn, Kdo-P, lipid A
907.8 1,362.7 2,727.5 2,726.3 0.4 PCho, 3Hex, 3Hep, 2PEtn, Kdo-P, lipid A
921.0 1,381.8 2,765.6 2,766.3 1.0 PCho, 4Hex, 3Hep, PEtn, Kdo-P, lipid A
961.9 1,443.7 2,889.0 2,889.3 0.9 PCho, 4Hex, 3Hep, 2PEtn, Kdo-P, lipid A
988.7 1,483.8 2,969.5 2,969.5 0.5 PCho, HexNAc, 4Hex, 3Hep, PEtn, Kdo-P, lipid A
1,029.6 1,544.9 3,091.9 3,092.5 0.9 PCho, HexNAc, 4Hex, 3Hep, 2PEtn, Kdo-P, lipid A
aAverage mass units were used for calculation of molecular weight based on proposed composition as follows: lipid A, 952.00; Hex, 162.15; HexNAc, 203.19; Hep,
192.17; Kdo-P, 300.16; phosphoethanolamine (PEtn), 123.05; and PCho, 165.05.
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demonstrated no reactivity ( phenotype) or strong ( phe-
notype) reactivity. Several of the MAb 4C4-reactive colonies
showed sectoring, indicating that the oligosaccharide extend-
ing from HepI included a digalactoside and that this was likely
expressed in a phase-variable manner (data not shown).
Electrospray ionization-MS analysis of the O-deacylated
LPS of strain RM118lex2tlpsA-k indicated a range of glyco-
forms containing between two and four hexose sugars (Table
1). Most glycoforms contained a PCho residue, and HexNAc
was detected in the highest-molecular-weight glycoform. Sugar
composition analysis of this glycoform suggested that the glu-
cose-to-galactose ratio was almost 1 to 1 and that the HexNAc
was GalNAc. 1H NMR analysis of the O-deacylated LPS of
strain RM118lex2tlpsA-k confirmed that the expression of
lex2 resulted in the addition of a second glucose to HepI of the
LPS, to which a digalactoside and finally a GalNAc residue
were added (Table 2). This analysis confirmed the absence
of sugar extensions from HepII and HepIII and the predic-
tion that the arrangement of and linkages between the sug-
ars of the oligosaccharide extending from HepI of strain
RM118lex2tlpsA-k (Gal-1,4-Gal-1,4-Glc-1,4-Glc-1,4-)
were indistinguishable from those of strain RM7004, except for
the addition of a terminal GalNAc.
Definition of the MAb 5G8-reactive epitope in strain
RM118lex2tlpsA-k by sequential immunoblotting. To further
characterize the epitope recognized by MAb 5G8 in strain
RM118lex2tlpsA-k, we conducted sequential colony immu-
noblotting using MAbs 5G8, 4C4, and TEPC-15. The latter
antibody binds PCho, which is located as a substituent of the
glucose attached directly to HepI (Fig. 1). Colonies of strain
RM118lex2tlpsA-k were grown on a plate and immunoblot-
ted with MAb 4C4, and the colonies was then regrown and
immunoblotted with MAb 5G8. The process was repeated for
immunoblotting with MAb TEPC-15. This approach allowed
superimposition of MAb binding patterns for individual colo-
nies. For MAb 5G8, as before, a minority of colonies demon-
strated the  phenotype while the majority of colonies were of
the  phenotype (Fig. 3A). Each of these MAb 5G8  phe-
notype variants corresponded exclusively to each of the col-
onies that demonstrated the MAb 4C4  phenotype (Fig.
3B). It can be concluded that expression of the MAb 5G8 
phenotype and that of the MAb 4C4  phenotype are
coincident in the LPS of strain RM118lex2tlpsA-k. The
third in the series of immunoblots using MAb TEPC-15 ex-
plained this behavior. For MAb TEPC-15, most of the colonies
reacted ( phenotype) while a minority of variants demon-
strated no reactivity ( phenotype) (Fig. 3C). Each of these
MAb TEPC-15-nonreactive variants corresponded to each of
the MAb 5G8  phenotype-4C4  phenotype variants.
From these results, we conclude that 5G8 specifically reacts
with the tetrasaccharide Gal-1,4-Gal-1,4-Glc-1,4-Glc-1,4-
extending from HepI and requires nonexpression of PCho in
that oligosaccharide and that the reactivity with MAb 4C4 is
diminished ( to ) but not abolished by the presence of
PCho.
Genetic modification of strain RM7004 to expose the 5G8-
reactive epitope. Since MAb 5G8 was raised against a Hib
strain (7), we wished to confirm our findings with Hib strain
RM7004, which naturally synthesizes LPS containing an oligo-
saccharide that we would predict to contain the MAb 5G8
epitope. In addition, we set out to determine whether the
FIG. 3. Sequential immunoblotting of colonies of strain RM118
lex2tlpsA-k5G8 with MAbs 5G8 (A), 4C4 (B), and TEPC-15 (C).
The levels of MAb binding by individual colonies are shown by arrows
and indicated by , , and  for reactivity, strong reactivity, and no
reactivity, respectively.
TABLE 2. 1H NMR chemical shifts for the O-deacylated




effectH-1 H-2 H-3 H-4 H-5
HepI 5.15 4.13 4.07 ND ND 4.31 Kdo, H-5
HepII 5.78 4.26 NDa ND ND 4.07 HepI H-3
HepIII 5.17 4.06 ND ND ND 4.26 HepII H-2
5.78 HepII H-1
-GlcN 5.40 3.77 ND ND ND
-Glc (GlcI) 4.56 3.61 3.70 3.70 3.70 4.26 HepI H-4
4.03 HepI H-6
-Glc (GlcII) 4.66 3.64 3.71 3.71 3.71 3.70 GlcI H-4
-Gal (GalI) 4.53 3.58 3.74 4.04 3.79 3.71 GlcII H-4
t--Gal (GalII) 4.94 3.83 3.90 4.02 ND 4.04 GalI H-4
-3--Gal (GalII) 4.91 3.88 3.95 ND ND 4.04 GalI H-4
-GalNac 4.62 3.94 3.75 ND ND 3.95 GalII H-3
-GlcN 4.62 3.90 3.80 ND ND ND
a ND, not determined.
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terminal GalNAc played any part in this epitope, as strain
RM7004 does not incorporate GalNAc into its LPS (21).
The genes lic2C and lpsA, which are known to be involved in
the addition of the first hexose to HepII and HepIII, respec-
tively, in this strain (Fig. 1A) (11), were inactivated to generate
strain RM7004lpsA-tlic2C-k. We anticipated that the outer
core LPS of this strain would consist of a tetrasaccharide ex-
tending from HepI only, nearly equivalent in composition to
the LPS from strain RM118lex2tlpsA-k but without the ter-
minal GalNAc residue and without PCho attached to the first
glucose. Unlike the parent strain RM7004, which did not react
with 5G8, the majority of colonies of strain RM7004lpsA-
tlic2C-k reacted strongly with this MAb (data not shown). Both
single mutants, RM7004lpsA-t and RM7004lic2C-k, reacted
with MAb 5G8, although less intensely than the double mutant
strain (data not shown). Upon sequential immunoblotting of
the double mutant strain with MAb 4C4, each of the MAb 5G8
 phenotype colonies reacted with MAb 4C4 and, conversely,
each of the MAb 5G8  phenotype colonies showed no reac-
tivity with MAb 4C4 (data not shown). None of the colonies
reacted strongly with MAb TEPC-15 (data not shown).
These findings confirmed our prediction that the LPS from
strain RM7004lpsA-tlic2C-k, which contains a natural tetrasac-
charide extending from HepI resembling that from strain
RM118lex2tlpsA-k but incorporates no terminal GalNAc,
was indeed 5G8 reactive.
Comparison of the MAb 5G8-reactive LPS glycoforms in
transformant strains of RM118 and RM7004 by Western anal-
yses. Strain RM118lex2tlpsA-k was enriched for MAb 5G8-
reactive cells by culturing a single MAb 5G8  variant colony
designated RM118lex2tlpsA-k5G8. Lysates were prepared
and then fractionated from this strain and nonenriched cells of
the following strains: RM118lex2tlpsA-k, RM118, RM7004,
RM7004lpsA-tlic2C-k, and DL42, a 5G8  control strain (15)
(Fig. 4A).
LPS bands of equivalent mobilities from strains RM118lex2
tlpsA-k5G8 and RM7004lpsA-tlic2C-k, as well as one from
strain DL42, reacted with MAb 5G8 upon immunoblotting.
The nonenriched strain RM118lex2tlpsA-k did not react (Fig.
4B). The lower-mobility band of strain RM118lex2tlpsA-
k5G8 LPS is presumed to correspond to the GalNAc- and
PCho-depleted LPS glycoform and did not react with MAb
FIG. 4. Fractionation and Western analysis of LPS molecules isolated from H. influenzae strains. Panel A shows the fractionation pattern after
tricine-sodium dodecyl sulfate-PAGE; results of Western analysis with MAbs 5G8 (B), 4C4 (C), and TEPC-15 (D) are shown below. Strains are
RM118 (lane 1), RM118lex2tlpsA-k5G8 (lane 2), RM118lex2tlpsA-k (lane 3), RM7004lpsA-tlic2orf3-k (lane 4), RM7004 (lane 5), and DL42
(lane 6) The estimated numbers of hexose sugars included in each glycoform are indicated by the scale on the right-hand side.
2218 GRIFFIN ET AL. INFECT. IMMUN.
5G8. Thus, it appears that 5G8 binds to the equivalent glyco-
forms of strains RM118lex2tlpsA-k and RM7004lpsA-
tlic2C-k. In a parallel experiment using MAb 4C4, LPS bands
of equivalent mobilities from strains RM118lex2tlpsA-k,
RM7004lpsA-tlic2C-k, and DL42 that reacted with MAb 5G8
reacted with MAb 4C4 also (Fig. 4C). This further supports
our finding that MAb 5G8 binds the oligosaccharide extending
from HepI that comprises a diglucoside and a terminal digal-
actoside. The presence of the GalNAc likely inhibits the bind-
ing of MAbs to the tetrasaccharide. TEPC-15 bound to LPS
glycoforms from strains RM118 and RM118lex2tlpsA-k,
both of which contain an abundance of PCho (Table 1; Fig.
4D) (23). Western analysis showed that the LPS of strain
RM118lex2tlpsA-k was recognized by MAb TEPC-15 and not
by MAb 5G8, confirming that the presence of PCho prevented
5G8 from binding to the LPS. Furthermore, the reduced bind-
ing of MAb 4C4 to the LPS of strain RM118lex2tlpsA-k
compared to that to the LPS of strain RM118lex2tlpsA-
k5G8 supports our earlier observation that the presence of
PCho reduces, but does not prevent, MAb 4C4 binding in
RM118lex2tlpsA-k. Unlike strain RM118, PCho is predomi-
nantly not expressed on the LPS of strain RM7004 (21) and
when expressed substitutes for the single galactose residue
extending from HepIII. Details of the structure of the LPS of
strain DL42 are not known.
Strain RM118lex2tlpsA-k displays altered serum resis-
tance. To investigate the biological relevance of the MAb 5G8-
reactive epitope in H. influenzae LPS, we studied the relative
levels of resistance of strain RM118 and its transformants to
the killing effect of pooled normal human sera. Typically, the
percent serum concentration required to kill 60% of wild-type
RM118 organisms was approximately 0.8%. With the lpsA mu-
tant, organisms were killed to the same level by approximately
0.2% serum. This relates to the loss of the digalactoside-incor-
porating oligosaccharide from the LPS of the RM118 lpsA
mutant strain (Fig. 5), confirming previous findings (11). How-
ever, in the lpsA mutant expressing lex2 (RM118lex2tlpsA-k),
the level of serum resistance was greatly increased to above
that found for the wild type, such that approximately 1.5%
serum was required to kill 60% of organisms of this strain (Fig.
FIG. 5. Resistance of H. influenzae strains to the killing effect of normal human serum. Representative results for strain RM118 and derived
mutants are shown. Organisms (5 	 102) were added to doubling dilutions of serum. Error bars from the averaging of the data from three
experiments are displayed.
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5). This level was diminished in two independent MAb 5G8 
phenotype variants of this strain, although the level of re-
sistance was greater than that of strain RM118. Strain
RM118lex2k showed a level of resistance to serum killing
similar to that of RM118lex2tlpsA-k. These findings enabled
us to draw the following conclusions.
The digalactoside extending from HepIII confers protection
against complement-mediated killing, as seen by the signifi-
cant reduction in resistance of the lpsA mutant. The oligo-
saccharide incorporating the digalactoside from HepI protects
organisms of strain RM118lex2tlpsA-k from complement-
mediated killing, as seen by the large increase in the sur-
vival rate of this strain compared to that of the wild type. In
RM118lex2tlpsA-k, despite the loss of the HepIII-linked di-
galactoside and therefore the subsequent loss of protection
conferred by this epitope, the expression of the digalactoside-
containing oligosaccharide from HepI overcompensates, al-
lowing significantly greater resistance to killing of this strain
than to that of the wild-type strain. This protection is mediated
by both digalactoside and PCho since MAb 5G8  phenotype
variants of this strain, lacking PCho, showed some diminution
in survival.
DISCUSSION
Of 126 Hib strains investigated by Gulig and coworkers, 74
strains (59%) reacted with MAb 5G8, suggesting that the ex-
pression of the LPS determinant recognized by this MAb is
relatively conserved in these clinical strains (7). Moreover, this
frequency is likely to be an underestimate since in the absence
of in vivo selection during in vitro passage, Hib strains are
reported to switch off the expression of their virulence-associ-
ated LPS epitopes that react with MAbs 5G8 and 4C4 (17, 33).
The association made between strains that are reactive with
MAb 5G8 and strains that are highly virulent and serum resis-
tant (16, 17) has generated much interest in elucidating the
structure of this LPS epitope.
The initial finding that MAb 5G8 reactivity was associated
with expression of the lex2 locus was key to our investigation
(15). The reactivity of colonies of Hib strains with 5G8 was
shown to be dependent upon a number of in-frame tetranucle-
otide repeats located within the lex2A gene (15). We previously
showed that the lex2 locus is required for the addition of a
second glucose to HepI of H. influenzae LPS to complete the
acceptor for a digalactoside (6). We set out to characterize the
structure of the MAb 5G8-reactive epitope in a strain devoid
of capsule, to prevent interference of capsule with our serum
resistance study, and expressing genetically characterized, min-
imally complex LPS. This strain, RM118, when transformed
with the lex2 locus acquired reactivity to MAb 5G8. To localize
the 5G8-reactive epitope within the LPS molecule, which we
predicted would extend from HepI, we further disrupted the
lpsA gene to prevent oligosaccharide extension from HepIII in
the lex2 transformant strain. LPS from this double mutant
strain retained MAb 5G8 reactivity and contained a single
tetrasaccharide capped by GalNAc extending from HepI of the
inner core. This tetrasaccharide was nearly identical to that
extending from HepI of the LPS of strain RM7004 except for
the presence of PCho, which is encoded by the phase-variable
locus lic1 (34). We showed by disrupting lic2C and lpsA in
strain RM7004 (Fig. 1) that this mutant strain has only a
tetrasaccharide extending from HepI which lacks GalNAc and
PCho and that these two moieties are not part of the MAb
5G8-reactive epitope. Thus, we have compelling evidence
that MAb 5G8 binds the tetrasaccharide Gal-1,4-Gal-1,4-
Glc-1,4-Glc-1,4 that extends from HepI of the LPS of
H. influenzae. This is the first complete genetic and structural
elucidation of an epitope binding an LPS-specific MAb in
H. influenzae.
Furthermore, we provide the first definitive evidence that
MAb 4C4 binds the digalactoside extending from HepI of
H. influenzae LPS in two strains, RM118lex2tlpsAk and
RM7004lic2C-klpsA-t, that extend sugars from HepI only.
Prior to this study, it was certain only that MAb 4C4 bound the
digalactoside extending from the second heptose in the LPS
molecules of Hib strains (32). Since MAb 4C4 does not bind to
the digalactoside-containing globotetraose that extends from
HepIII of the LPS of strain RM118, we speculate that the
recognition of the digalactoside by MAb 4C4 is influenced by
the location of the epitope and the structural conformation of
the complete LPS molecule. It may be that the diglucoside
acceptor synthesized prior to the digalactoside is essential for
MAb 4C4 binding. This acceptor is available as an extension
from both HepI and HepII in strain RM7004 (21), whereas
HepIII is replaced by only a single glucose in strain RM118
(23).
The two MAbs 4C4 and 5G8 differ in their degrees of spec-
ificity of binding. MAb 4C4 recognizes the digalactoside-con-
taining tetrasaccharide regardless of whether it extends from
HepI or HepII, whereas MAb 5G8 binds exclusively the digal-
actoside-containing tetrasaccharide extending from HepI. In
the presence of PCho linked to the glucose attached to HepI,
MAb 4C4 binding is reduced, whereas MAb 5G8 binding is
abolished.
In all Hib strains with characterized LPS molecules, there is
no PCho substituting for the glucose attached to HepI. Rather,
PCho is attached to the hexose extending from HepIII, where
it would not appear to influence MAb 5G8 binding, as seen in
our RM7004-derived strains.
It is clear from this study that the MAb 5G8 epitope confers
significant resistance to serum killing, and this finding allows us
to understand the association made previously between MAb
5G8 reactivity and virulence in type b strains. Since the LPS
epitope in question incorporates a digalactoside and this epi-
tope is reported to mimic human antigens found on a variety of
cell types, including erythrocytes, protection occurs through
presentation of a “self antigen” (32). The digalactoside extend-
ing from the third heptose also appeared to confer serum
resistance, as seen by the large decrease in resistance of the
lpsA mutant to serum.
Strain RM118lex2k can synthesize oligosaccharides from
both HepI and HepIII, along with PCho, and therefore may
have been expected to be the most resistant strain. However,
this strain did not survive as well as RM118lex2tlpsA-k. In
strain RM118lex2k, only a minority of glycoforms contain
fully extended oligosaccharides incorporating the digalactoside
(Table 1). In contrast, in strain RM118lex2tlpsA-k, the ma-
jority of glycoforms incorporate the digalactoside (Table 1).
PCho contributed to the serum resistance of RM118lex2
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tlpsA-k, as seen by some reduction in resistance in the PCho-
negative variants.
In summary, the digalactosides included in oligosaccharide
extensions from both HepI and HepIII in H. influenzae LPS
confer resistance to killing by human serum and PCho plays a
role in this protection.
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